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Background: Cost-effectiveness analyses (CEAs) that use patient-specific data from a randomized controlled trial
(RCT) are popular, yet such CEAs are criticized because they neglect to incorporate evidence external to the trial. A
popular method for quantifying uncertainty in a RCT-based CEA is the bootstrap. The objective of the present study
was to further expand the bootstrap method of RCT-based CEA for the incorporation of external evidence.
Methods: We utilize the Bayesian interpretation of the bootstrap and derive the distribution for the cost and
effectiveness outcomes after observing the current RCT data and the external evidence. We propose simple
modifications of the bootstrap for sampling from such posterior distributions.
Results: In a proof-of-concept case study, we use data from a clinical trial and incorporate external evidence on the
effect size of treatments to illustrate the method in action. Compared to the parametric models of evidence
synthesis, the proposed approach requires fewer distributional assumptions, does not require explicit modeling of
the relation between external evidence and outcomes of interest, and is generally easier to implement. A drawback
of this approach is potential computational inefficiency compared to the parametric Bayesian methods.
Conclusions: The bootstrap method of RCT-based CEA can be extended to incorporate external evidence, while
preserving its appealing features such as no requirement for parametric modeling of cost and effectiveness
outcomes.
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Randomized controlled trials (RCTs), especially ‘prag-
matic’ RCTs that measure the effectiveness of interven-
tions in realistic settings, are an attractive opportunity to
provide information on cost-effectiveness [1]. In the con-
text of such a RCT, many aspects of treatment from clin-
ical outcomes to adverse events and costs are measured at
the individual level, which can be used to formulate an
efficient policy based on cost-effectiveness principles. A
growing number of trials incorporate economic endpoints* Correspondence: msafavi@mail.ubc.ca
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article, unless otherwise stated.at the design stage and there are established guidelines for
conducting a cost-effectiveness analysis (CEA) alongside a
RCT [2,3].
The statistic of interest in a CEA is the incremental
cost effectiveness ratio (ICER), which is defined as the
difference in cost (ΔC) between two competing treatments
over the difference in their health outcome (effectiveness)
(ΔE). With patient-specific cost and health outcomes at
hand, estimating the population value of the ICER from
an observed sample becomes a classical statistical infer-
ence problem. However, given the awkward statistical
properties of cost data and some health outcomes such as
quality-adjusted life years (QALYs), and issues around
parametric inference on ratio statistics, many investigators
choose resampling methods for quantifying the sampling
variation around costs, health outcomes, and the ICER [4].
In parallel-arm RCTs, this can be performed by obtainingtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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lating the mean cost and effectiveness within each arm
from the bootstrap sample; repeating this step many times
provides a random sample from the joint distribution of
arm-specific cost and effectiveness outcomes. This sample
can then be used to make inference on (such as calculate
the confidence or credible interval for) the ICER [5].
Recently, such a framework for evaluating the cost and
outcomes of health technologies has received some criti-
cism [6-8]. Specifically, critics argue that making deci-
sions on the cost-effectiveness of competing treatments
should be based on all the available evidence, not just
those obtained from a single RCT [8]. In this context,
evidence synthesis is the practice of combining multiple
sources of evidence (from other RCTs, expert opinion,
and case histories) in informing the treatment decision,
a task that is quantitatively performed using the Bayes’
rule [9].
A conventional analysis of a clinical trial often involves
making inference primarily on the effect size and sec-
ondarily on other aspects of treatment such as safety or
compliance. These measures are conceptually distinct
enough to be analyzed and reported separately and trial-
ists have a full arsenal of standard statistical methods at
their grasp for such analyses. Evidence synthesis is often
conducted separately, usually through quantitative meta-
analysis, after the results of several studies are available.
An economist, on the other hand, does not have the lux-
ury of dissecting RCT results into different components
as cost-effectiveness is a function of all aspects of an
intervention. As such, evidence external to the trial on
any aspect of treatment has bearings on the results of
the CEA. In addition, when a RCT is used as a vehicle
for the CEA the incorporation of external evidence must
be part of the analysis. Results of a CEA have direct policy
implications and the economist cannot defer evidence
synthesis to any subsequent stage [8].
For trial-based CEAs, if external evidence on cost or
effectiveness is available then the investigator can use
standard parametric Bayesian methods to combine this
information with trial results [9]. This has been the
dominant paradigm in the Bayesian analysis of RCT-based
CEAs [10-14]. However, prior information on cost and
typical effectiveness outcomes such as QALY is rarely
available and if it is, it is often inappropriate to transfer to
other settings [15,16]. This is because such outcomes are,
to a large extent, affected by the specific settings in the
jurisdiction in which they are measured (such as unit
prices for medical resources). On the other hand, evidence
on the aspects of the intervention that relate to the
pathophysiology of the underlying health condition and
the biologic impact of treatment, such as the effect size
of treatment or rate of adverse events, are less affected
by specific settings and are therefore more transferable[17]. This puts the investigator in a difficult situation
for a RCT-based CEA as inference is made directly on
cost and effectiveness using the observed sample, but
evidence is available on some other aspects of treat-
ment. One way to overcome this challenge is to create a
parametric model to connect cost-effectiveness outcomes
with parameters for which external evidence is available,
and use Bayesian analysis, for example through Markov
Chain Monte Carlo (MCMC) sampling techniques
[18]. But such a model must connect several parame-
ters through link functions, regression equations, and
error terms. This involves a multitude of parametric
assumptions and there is always the danger of model
misspecification [19,20]. In addition, even with the
advent of generic statistical software for Bayesian ana-
lysis, implementing such a model and comprehensive
model diagnostics are not an easy undertaking. For an
investigator using resampling methods for the CEA
who wishes to incorporate external evidence in the
analysis, this paradigm shift to parametric modeling
can be a challenge.
In this proof-of-concept study, we propose and illus-
trate simple modifications of the bootstrap approach for
RCT-based CEAs that enable Bayesian evidence synthesis.
Our proposed method requires a parametric specification
of the external evidence while avoiding parametric as-
sumptions on the cost-effectiveness outcomes and their
relation with the external evidence. The remainder of the
paper is structured as follows: after outlining the context,
a Bayesian interpretation of the bootstrap is presented.
Next, the theory of the incorporation of external evidence
into such sampling scheme is explained. A case study
featuring a real-world RCT is used to demonstrate the
applicability and face validity of the proposed method.
A discussion section on the various aspects of the new
method and its strengths and weaknesses compared to
parametric approaches concludes the paper.Methods
Context
Let θ = {θi, θe} be the set of parameters to be estimated
from the data of a RCT and some external evidence. It
consists of two subsets: θi, the parameter (s) of interest
for which there is no external evidence, and θe, some pa-
rameters for which external evidence is available. Typic-
ally, θi includes cost and effectiveness outcomes, and θe
consists of some biological measures of treatment such
as treatment effect. Let D represent the individual-level
data of the current parallel-arm RCT, fully available to
the investigator. We assume the population of interest
for inference is the same as the population from which
D is obtained, a fundamental assumption in any RCT-
based CEA.
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In a Bayesian context, the problem of inference on θ
from a sample D can be conceptualized as incorporating
some prior information with the information provided
by the data to obtain a posterior distribution for θ:
P θ DÞ∝π θð Þ:P D θÞjðjð ð1Þ
omitting a normalizing constant which is the function
of D, but not θ. Here π(θ) is our prior distribution on
θ, P(D|θ) is the likelihood of current data, and P(θ|D)
is the posterior distribution having observed the trial
data D. If prior and posterior distributions are from a
parametric family indexed by a set of distribution pa-
rameters, then a fully parametric model can be used to
draw inference on P(θ|D). However, one can perform such
Bayesian inference non-parametrically: Rubin showed that
if we assume a prior non-informative Dirichlet distribution
for D itself (regardless of which parameter to estimate),
then we can directly draw from P(θ|D) using a simple
process called the Bayesian bootstrap [21]. In the Bayesian
bootstrap of a dataset D consisting of n independent ob-
servations, a probability vector P = (p1, …, pn) is gener-
ated by randomly drawing from Dirichlet(n; 1, …, 1).
The probability distribution that puts the mass of pi on
the ith observation in D can be considered a random
draw from the ‘distribution of the distribution’ that has
generated D. Let D* represent a bootstrapped sample of
D generated in this way, then according to the argument
made above, θ*, the value of θ measured in this sample,
is a random draw from P(θ|D) [21].
Ordinary bootstrap as an approximation of the Bayesian
bootstrap
The process of ordinary bootstrap can also be seen as
generating a probability vector to the data, except only the
probability vector is generated from the scaled multinomial
distribution [22]. Such a process does not mathematically
correspond to formal Bayesian inference. Nevertheless, the
similarity in both the operation and results to the Bayesian
bootstrap has led some investigators to interpret the ordin-
ary bootstrap in a Bayesian way [23]. For example, the
widely popular non-parametric imputation of missing data
uses ordinary bootstrap as an approximate to the Bayesian
bootstrap [22,24]. Indeed, it has already been shown that
the ordinary and Bayesian bootstrap methods generate very
similar results in non-parametric value of information ana-
lysis of RCT data [21]. Given this, for the rest of this work
we use Bayesian and ordinary bootstraps interchangeably.
CEA without the incorporation of external evidence
In a CEA in which we do not intend to incorporate any
external evidence the quantity of interest for inference is
P(θ|D). As described in the previous section, a samplefrom this quantity can be obtained using a simple
resampling algorithm:
1 For i = 1,…,M, where M is the number of bootstraps:
a. Generate D*, a (Bayesian) bootstrap sample with
bootstrapping performed within each arm of the
trial.
b. Calculate θ* from D*.
2 Store the value of θ* and jump to 1.
This approach generates M random draws from the
posterior distribution of θ having observed the RCT
data. This is indeed the widely popular bootstrap
method of RCT-based CEA [4]. An estimator for the
ICER from the bootstrapped data can be obtained by
calculating the ratio of the mean cost over mean effective-
ness from the bootstrap samples [4]. Various methods can
be used to construct a credible interval from the boot-
strapped samples around this value [4,25]. These samples
can also be used to present uncertainty in the form of a
cost-effectiveness plane or cost-effectiveness acceptability
curve (CEAC) [26].
Incorporating external evidence
Let De be some external data providing evidence on θe. While
the external data is not fully available to the investigator,
evidence is available most typically in the form of the
external likelihood P(De|θe), for example, recovered from
the reportedmaximum likelihood estimate and confidence
bounds of treatment effect from a previously published
study. We require D and De to be independent samples.
This is a typical and fundamental assumption in evidence
synthesis, for example in meta-analysis of treatment effect
from multiple trials. By our definition of θi and θe, we
know that the external likelihood only provides informa-
tion on θe (the information on θi is either not collected or
is not reported by the investigators of the external study).
As such, the external likelihood is a marginal likelihood
for θe and hence is not a function of θi. We also note that
sometimes external evidence is obtained through a more
subjective process, such as elicitation of expert opinion. In
such cases, De becomes an abstract entity and P(De|θe)
can be seen as a ‘weight’ function representing the degree
of plausibility of θe against external knowledge.
In the presence of external data De, the quantity of
interest is P(θ|D, De), which can be expanded, through
three steps, as:
P θi; θejD;Deð Þ∝π θi; θeð Þ:P D;Dej θi; θeð Þ∝π θi; θeð Þ:
P D θi; θeÞ:P De θi; θeÞ∝P θ DÞ:P De θeÞjðjðjðjð
ð2Þ
In the above derivations, in the first step we have applied
the Bayes rule; the second step factorizes the likelihood
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and the third step is based on the fact that the external
data provides no information about θi (that is, P(De| θi, θe)
is not a function of θi), so the likelihood term P(De| θi, θe)
is reduced to P(De|θe).Sampling from the posterior distribution
Suppose that a random sample can be generated from
an ‘easy’ distribution g, but we are actually interested in
obtaining a sample from a ‘difficult’ distribution h. How
can we use the samples from g to obtain samples from h?
Two popular methods for converting samples from g to h
are rejection sampling [27] and importance sampling [28];
both are based on applying weights proportional to
density ratio h/g to each observation from g. In the
present context, g = P(θ|D) and h = P(θ|D, De); the weights
are, according to (Equation 2), proportional to P(De|θe).
That is, to obtain samples from P(θ|D, De), each θ* as a
sample from P(θ|D), obtained through bootstrapping,
needs to be weighted by P De θ

eÞ
 . To operationalize
this, we propose two approaches based on rejection and
importance sampling schemes. The reader can refer to
Smith and Gelfand for an elegant elaboration on these
two sampling schemes (along with the derivations) [27].Rejection sampling
In this scheme, each D*, the entire bootstrap sample of the
RCT data, is accepted by a probability that is proportional
to P De θ

eÞ
 , the weight of θe obtained from D*. This
results in the following algorithm:
1 For i = 1,…,M, where M is the desired size of the
sample:
a. Generate D*, a (Bayesian) bootstrap sample of D,
with bootstrapping performed separately within
each arm of the trial.
b. Calculate the parameters θ ¼ θi ; θe
 
from
this sample.
c. Calculate P ¼ P De θe Þ
 , the weight of θe
according to external evidence.
d. Randomly draw u from a uniform distribution in
the interval [0,1]. If u > P* , then ignore the
bootstrap sample and jump to step a.2 Store the value of θ* and jump to 1.
This approach generates M random draws from the
posterior distribution of θ having observed the RCT data
and the external evidence. All the subsequent steps of
the CEA, such as calculating the average cost and effective-
ness outcomes, interval estimations, and drawing the cost-
effectiveness plane and the CEAC, remain unchanged. Of
note, this algorithm requires that P* be valid probabilitiesbounded between 0 and 1. As such, the external likelihood
should be scaled (e.g., divided by maxθe P De θej Þð ½ ).Importance sampling
As an alternative to probabilistically accepting or reject-
ing bootstrap samples one can assign the weights directly
to each bootstrap sample [27]. That is, one proceeds by
obtaining a desired number of bootstraps, calculating θe
in each sample, and assigning a weight proportional to
P De θ

eÞ
 to each bootstrap. All subsequent calculations
require incorporating such weights (for example, ICER
will be the ratio of the weighted mean of costs over the
weighted mean of effectiveness).Regularity conditions
Fundamental to the proposed sampling scheme is that
the joint likelihood of D and De can be factorized into
two independent likelihoods. The onus is on the investi-
gator to ensure this condition is satisfied with at least a
good approximation. This can be context-specific. A few
scenarios that violate this assumption are when D and
De have overlapping samples, when De is an estimate
from a meta-analysis of studies that included the current
study D, or when De represents experts’ opinion about
treatment effect if their opinion is already influenced by
the results of the current study (the hindsight bias [29]).
In addition, the general regularity conditions required
for the rejection and importance samplings should hold
[27]. Particularly, since P(θ|D) is most often continuous
(or for the regular bootstrap it takes many discrete
values), the external likelihood P(De|θ), should also be
continuous, otherwise the chance of samples from P(θ|
D) hitting non-zero areas of P(De|θ) will be infinitely
small. Next, θe should be identifiable (unique) within
each D*. This assumption holds for the most typical
form of external evidence such as rates or measures of
relative risk [30]. Further, P(De|θ) should be bounded. If
P(De|θ) has an infinite maximum, for example, if it is
proportional to the density function of a beta distribu-
tion with either of its parameters being less than one the
proposed sampling schemes might fail. Such distributions
are, however, mainly used as non-informative priors and
seldom represent external evidence in realistic scenarios.
On the other hand, mixed-type distributions such as the
so called lump-and-smear priors that put point mass on
the value of the parameter consistent with the null hy-
pothesis ([31] page 161), have unbounded density func-
tions and cannot readily be used in the proposed sampling
methods.
We used data from a real-world RCT to show the prac-
tical aspects of implementing the proposed algorithms.
Ethics approval was obtained from the Ottawa Hospital
Sadatsafavi et al. Trials 2014, 15:201 Page 5 of 9
http://www.trialsjournal.com/content/15/1/201Research Ethics Board (#2002623-01H) and Vancouver
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Results
An illustrative example
This case study is to demonstrate the operational aspects
of implementing the algorithm and is not intended to
be a practice in comprehensive evidence synthesis to
inform policy.
The case study is based on the OPTIMAL trial, a
multicenter study evaluating the benefits of combination
pharmacological therapy in preventing respiratory exac-
erbations in patients with chornic, obstructive pulmon-
ary disease (COPD) [32,33]. Pharmacological treatment
of COPD, typically with inhaled medications, is often re-
quired to keep the symptoms under control and reduce
the risk of exacerbations. Sometimes patients receive
combinations of treatments of different classes in an at-
tempt to bring the disease under control. However, there
is a lack of evidence on whether such combination ther-
apies are effective. The OPTIMAL trial was designed to
estimate the comparative efficacy and cost-effectiveness
of single and combination therapies in COPD. It in-
cluded 449 patients randomized into three treatment
groups: T1: monotherapy with an inhaled anticholinergic
(tiotropium, N = 156); T2: double therapy with an
inhaled anticholinergic plus an inhaled beta-agonist (tio-
tropium + salmeterol, N = 148); and T3: triple therapy
with an inhaled anticholinergic, an inhaled beta-agonist,
and an inhaled corticosteroid (tiotropium + fluticasone
+ salmeterol, N = 145). The primary outcome measure
of the RCT was the proportion of patients who experi-
enced at least one respiratory exacerbation by the end of
the follow-up period (52 weeks). This outcome was not
significantly different across the three arms: the odds ra-
tio (OR) for the risk of having at least one exacerbation
by the end of the follow-up period was 1.03 (95% CI,
0.63 to 1.67) for T2 versus T1 and 0.84 (95%CI, 0.47 to
1.49) for T3 versus T1 (lower OR indicates a better
outcome). Because the T2 arm in the OPTIMAL trial
was dominated (was associated with higher costs and
worse effectiveness outcomes) in the original CEA, and
for the sake of brevity, in this case study we restrict the
analysis to a comparison between T3 and T1.
Details of the original CEA are reported elsewhere
[34]. Data on both resource use and quality of life were
collected at individual level during the trial, which was
used to carry out the CEA. The main outcome of the
CEA was the incremental costs per QALY gained for T3
versus T1 (that is, the difference in mean costs over the
difference in mean QALYs). Since individual level resource
use and effectiveness outcomes were available, the CEA
was based on the direct inference on their distribution. Noexternal information was incorporated in the analysis in
the original CEA.
External evidence
The set of parameters with external evidence in this ana-
lysis (θe) consists of one quantity: the logarithm of rate
ratio (RR) of exacerbations between T3 and T1 (denoted
by θT3,T1) within the follow-up period. We used a formal
process for evidence synthesis by performing a MED-
LINE search for all clinical trials as well as systematic
reviews on the treatment effect of combination pharma-
cotherapies for COPD. In synthesizing evidence, we
assumed a ‘class effect’ for the study medications, in line
with conventional wisdom and several pharmacoepide-
miology studies evaluating such medications in COPD
[35-37]. The most relevant source of evidence on the ef-
fect size of T3 versus T1 was from a RCT on comparing
budesonide (in the same class as fluticasone) and formo-
terol added to tiotropium versus tiotropium alone in
COPD patients [38]. This study reported a RR of 0.38
(95% CI 0.25 to 0.57). The evidence was parameterized
by using normal likelihoods on the log-RR scale. When
transferring evidence form one setting to another it is
important to consider the likely presence of between-
study variation (due to difference in inclusion criteria,
treatment protocol, measurements, and so on) [39]. Be-
cause only one study on this comparison was at hand, no
estimate for between-study variation could be obtained.
As such, we use the estimated between-study variance
of 0.01783 from the multiple-treatment comparison of
COPD treatments (personal communication with the
author K Thorlund) [35]. This results in the external
evidence being associated with a RR of 0.38(95% CI 0.24
to 0.59), thus:
log RR eNormal μ; σð Þ; μ ¼ −0:968; σ ¼ 0:246 ð3Þ
with μ and σ corresponding to the mean and standard
deviation of the normal distribution. We note that the
uncertainty around the log-RR from external evidence,
represented by the above probability distribution, stems
from two sources: the finite sample of the external study,
and our assumption on between-study variability. Over-
all, the RR representing external evidence is much more
in favor of combination therapy than the RR observed
in the OPTIMAL trial. As such, we a priori expect that
the incorporation of external evidence shall improve the
cost-effectiveness outcomes in favor of T3.
Putting all these together, the external evidence can be
parameterized as:
P Dejθð Þ∝e−
θT3;T1−μð Þ2
2σ2 ∝e−
θT3;T1þ0:968ð Þ2
0:121 ð4Þ
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ledge on treatment effect. The original algorithm for the
CEA can now be updated to incorporate the external
evidence as follows (using the rejection sampling scheme):
1 For i = 1,2,…,M.
a. Generate D*, a (Bayesian) bootstrap sample within
each of the three arms of the RCT.
b. Impute the missing values in costs, utilities, and
exacerbations in D*.
c. Calculate θT3;T1, the log(RR) of exacerbation during
the follow-up period for T3 vs. T1 from the bootstrapped
sample.
d. Calculate P ¼ P θT3;T1
 
using the distribution
constructed for the external evidence.
e. Randomly draw u from a uniform distribution in the
interval [0,1]. If u >P, then ignore the bootstrapped
sample and jump to step a.
f. . Calculate mean costs, exacerbations, and QALYs
for each arm from D*.
2 Store the average values for costs, exacerbation rates,
and QALYs; then jump to 1.
The simulation was stopped after 10,000 accepted boot-
straps for the rejection sampling method incorporating
the external evidence were generated. To obtain the re-
sults using the importance sampling method, we used the
same set of bootstraps generated in the above algorithm,
including all the accepted and rejected bootstraps.
In addition to the ICER, we also reported the expected
values of the cost and health outcomes for each trial
arm, and also plotted the CEAC, without and with the
incorporation of the external evidence. The CEAC be-
tween two treatments is the probability that a treatment
is cost-effective compared to another at a given value of
the decision-maker’s willingness-to-pay (λ) for one unit
of the health outcome [26]. The statistical code for this
case study is provided in Additional file 1.Table 1 Outcomes of the OPTIMAL CEA without and with the
T1
No external evidence
Bayesian bootstrap Costs 2649 (466)
QALY 0.7071 (0.0075)
Ordinary bootstrap Costs 2650 (467)
QALY 0.7071 (0.0075)
With external evidence
Bayesian bootstrap Costs 2753 (492)
QALY 0.7053 (0.0074)
Ordinary bootstrap Costs 2742 (477)
QALY 0.7054 (0.0074)
*Results are mean (standard deviation).
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.Results of the case study
Table 1 presents the expected value costs and QALYs for
the T1 and T3 arms of the OPTIMAL trial without and
with the incorporation of the external evidence. The
Bayesian and ordinary bootstraps generated very similar
results (Table 1). Similarly, results from the rejection and
importance sampling methods were very similar (results
not shown).
As this table demonstrates, the incorporation of external
evidence shifted the outcomes of the T3 arm in the favor-
able direction (lower costs and higher QALYs), and shifted
the outcomes of the T1 arm in the opposite direction. This
is an expected finding given the strong evidence in favor
of T3 for the effect size of T3 versus T1 from the external
source.
The impact of incorporating external evidence is more
evident on the ICER. The ICER of T3 versus T1 de-
creased by 52% after the incorporation of external evi-
dence. Again, this is reflective of the fact that external
evidence is more in favor of T3 than the likelihood
(RCT data) is.
Figure 1 presents the results of incorporating external
evidence on the CEAC (using the Bayesian bootstrap).
The incorporation of external evidence increased the
probability of cost-effectiveness for T3, especially with
higher willingness-to-pay (λ) values. Without the incorp-
oration of external evidence, the probability of T3 being
cost-effective compared to T1 reach the 50% threshold at
λ values greater than $240,000/QALY, while the incorpor-
ation of the external evidence moved this threshold to
$115,000/QALY.
Discussion
Contemporarily, when an economic evaluation is con-
ducted alongside a single RCT, the practice of evidence
synthesis is not an integral part of the analysis. In our
opinion, this is partly because parametric Bayesian
modeling, the hitherto only available method, results inincorporation of external evidence*
T3 Difference (T3 – T1) ICER
4074 (547) 1425 (721) 250,329
0.7128 (0.0093) 0.0057 (0.0087)
4077 (551) 1427 (721) 251,171
0.7128 (0.0093) 0.0057 (0.0087)
3959 (510) 1205 (709) 121,260
0.7152 (0.0092) 0.0099 (0.0085)
3966 (536) 1225 (709) 126,387
0.7151 (0.0092) 0.0098 (0.0084)
Figure 1 Cost-effectiveness acceptability curve (CEAC) without and with the incorporation of external evidence. The horizontal grey line
represents the 50% threshold on probability of cost-effectiveness.
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work we propose simple and intuitive algorithms for the
incorporation of external evidence in RCT-based CEAs
that use bootstrapping to draw inference. Rejection and
importance samplings which form the basis of the pro-
posed method are popular paradigms in which sampling
from a ‘difficult’ distribution is replaced by sampling from
a proposal (or instrumental) distribution [40]. Here,
sampling from P(θ|D,De) is performed via P(θ|D), and
the latter can easily be sampled through (Bayesian)
bootstrapping.
In synthesizing evidence for RCT-based CEAs, a care-
fully crafted parametric model with comprehensive ana-
lysis of model convergence and sensitivity of results to
parametric assumptions has indisputable strengths over
resampling approaches, including the higher computa-
tional efficiency of MCMC or likelihood-based methods
and the ability to synthesize and propagate all evidence
in a single analytical framework [41,42]. Nevertheless,
important advantages make the proposed resampling
methods a competitive option. The proposed methods
are intuitive and easy extensions of the popular boot-
strap method of RCT-based CEAs; they do not require
specialist software and in-depth content expertise for
implementation. In addition to such practical advantages,
the proposed resampling methods connect the parametersfor which external evidence is available to the cost and
effectiveness outcomes without an explicit model, which
is a requirement in parametric Bayesian approaches.
Our paper provides a conceptual framework and further
research into theory, as well as practical issues in using
this method, should follow. The apparent simplicity of
the bootstrap may conceal the assumptions being made,
especially with small datasets [21,43]. Furthermore, if
the external evidence and RCT data substantially differ
on the information they provide for the evidence (that
is, that the prior and data are in conflict) [44], or when
there are multiple parameters for which external evidence
is available, then the sampling methods will become
inefficient.
Further research is needed to improve sampling effi-
ciency and to incorporate external evidence in other
paradigms such as cluster or crossover RCTs. Import-
antly, the theoretical construct of the proposed method
does not necessarily restrict it to RCT-based CEAs. A
similar concept can be used to reconcile evaluations
based on observational data with external evidence. This
will inevitably invoke questions about the applicability of
different metrics of the effect size in non-randomized
studies (for example, average treatment effect versus
average treatment effect for the treated), and the validity
of the bootstrap as the sampling method (for example,
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further empirical research is required to evaluate the
real-world applicability and feasibility of the method
and to demonstrate its comparative performance against
conventional methods of evidence synthesis (for example,
parametric Bayesian analysis using MCMC).
This paper deliberately stays away from the debate on
whether to incorporate external evidence for a given
situation an d focuses on the ‘how to’ question. The
‘whether to’ question is context-specific and great care is
required for the sensible use of external evidence in each
setting. For the case study, for example, the substantial
discrepancy in the results between the external and
current RCTs (with regard to the efficacy of triple therapy
versus monotherapy) should more than anything generate
misgivings about the suitability of borrowing evidence
from that external source. However, the case study was
undertaken as a step in the direction of proof of concept,
applicability, and face validity of the proposed methods.
This is not a withdrawal from the deep considerations
required for sensible evidence synthesis.
Conclusions
Faced with the escalating costs of RCTs and the requirement
by many decision-making bodies for formal economic evalu-
ation of emerging health technologies, trialists and health
economists are hard-pressed to generate as much relevant
information for policymakers as possible. As such, and des-
pite criticisms, it appears that RCT-based CEAs are here to
stay. The incorporation of external evidence helps optimize
adoption decisions. Aside from their theoretical contribu-
tion, if their real-world applicability is proven the proposed
methods can provide the large camp of analysts using boot-
strap for RCT-based CEAs with a statistically sound, easily
implementable tool for such purpose.
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